Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 1 (January)

1. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
   Clin Cancer Res, 13(1): 228-33. [Abstract] [Full-text]
2. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
   Lancet, 369(9555): 29-36. [Abstract] [Full-text]
3. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer.
   Cancer Res, 67(1): 269-75. [Abstract] [Full-text]
4. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.
   Cancer Res, 67(1): 254-61. [Abstract] [Full-text]
5. Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.
   Cancer Genet Cytogenet, 172(2): 95-106. [Abstract] [Full-text]
6. Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
   J Cutan Pathol, 34(1): 49-54. [Abstract] [Full-text]
7. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
   Breast J, 13(1): 72-5. [Abstract] [Full-text]
8. New agents in development for breast cancer.
   Curr Opin Obstet Gynecol, 19(1): 68-74. [Abstract] [Full-text]
9. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
   Curr Opin Obstet Gynecol, 19(1): 56-62. [Abstract] [Full-text]
10. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy.
    Cancer Res, 67(2): 433-6. [Abstract] [Full-text]
11. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
    Int J Radiat Oncol Biol Phys, 67(2): 405-9. [Abstract] [Full-text]
12. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.
    Mol Cancer Ther, 6(1): 227-35. [Abstract] [Full-text]
13. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
    Br J Cancer, 96(2): 269-76. [Abstract] [Full-text]
14. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Breast Cancer Res Treat, 101(3): 355-65. [Abstract] [Full-text]
15. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Cancer, 109(3): 496-501. [Abstract] [Full-text]
16. Breast cancer: The upgraded role of HER-3 and HER-4.
    Int J Biochem Cell Biol. [Abstract] [Full-text]
17. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
    Cancer Treat Rev, 33(1): 64-77. [Abstract] [Full-text]
18. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
    Mol Cancer Res, 5(1): 71-85. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.